Epidemiologic evidence linking environmental exposure to polycyclic aromatic hydrocarbons (PAH) with breast cancer is limited. Measurement of DNA adducts formed by aromatic compounds, including PAH, has been carried in breast tissue samples and white blood cells from women with breast cancer and different kinds of controls. However, these studies provide inconsistent results and bias cannot be ruled out. During the 7-year follow-up period, 305 women were diagnosed with first primary breast cancer in the EPICSpain cohort, and were compared with a sample of 149 women without breast cancer at recruitment, using a case-cohort approach. Aromatic adducts to DNA from leukocytes collected at recruitment were measured by means of the 32 P-post-labelling technique. The relative risk and 95% confidence interval (CI), adjusted by relevant confounders, were estimated by a modified version of Cox proportional hazards model. There was a significant increased risk for developing breast cancer when DNA adduct concentrations were doubled, with adjusted RR of 1.61 (95% CI 1.29-2.01). The increase in breast cancer risk was observed both for pre-and postmenopausal women. There was a significant interaction with tobacco smoking and body mass index, with higher effect of DNA adducts on breast cancer risk among smokers and women with normal weight. The results from our study support the hypothesis that factors leading to higher levels of aromatic DNA adducts in white blood cells may be involved in development of breast cancer.
Introduction
Thus far, many correlates of breast cancer risk have been identified, including a constellation of hormone-related reproductive factors; other risk factors include obesity, lack of regular exercise and alcohol consumption. However, known risk factors taken together can only account for some percentage of the breast cancer risk, suggesting that additional factors remain to be discovered (1, 2) . Studies on temporal and geographic variation of breast cancer incidence, as well as studies showing that women who migrate from areas of low risk to areas of high risk assume the rate in the host country within one or two generations (3, 4) , suggest that environmental factors are important in the occurrence of breast cancer.
Laboratory research has shown that several environmental pollutants are able to mimic estrogen activity and may affect susceptibility of the mammary gland to carcinogenesis. Polycyclic aromatic hydrocarbons (PAH) have been shown to cause mammary tumors in animals, probably in conjunction with genetic polymorphisms involved in carcinogen activation and metabolism (5, 6) . Epidemiologic evidence linking environmental exposure to PAH with breast cancer is limited. There is no consistent pattern of association between breast cancer risk and the main sources of PAH exposure, including air pollution, tobacco smoking and diet (7) (8) (9) . Therefore, despite positive associations in animal models, the carcinogenicity of these chemical compounds on the human breast remains unclear.
Aromatic compounds, including PAH, form metabolites which can covalently bind to DNA and form adducts and when left unrepaired can lead to altered DNA replication. Bulky DNA adducts are used as biomarkers providing an integrated measurement of exposure, metabolic activation and detoxification, and repair mechanisms of DNA damage by aromatic compounds (10, 11) . Measurement of DNA adducts has been carried out in breast tissue samples from women with breast cancer and different kinds of controls by means of either 32 P-post-labelling method (12, 13) or immunohistochemical assays (14) (15) (16) . In most instances, the DNA adduct level was higher in breast tissue from women with cancer (12, 13, 15) . However, these studies had a relatively small number of subjects, and some did not include a true control group or controls lacked internal consistency to ensure that they represent the population from which the cases arose. Therefore, they provide unstable results and bias cannot be ruled out.
A large population-based case-control study measured PAH-DNA adducts by means of immunoassay method in leukocytes. A significant increase in risk was found for high levels of adducts in the original study (8) as well as in a pooled analysis (17) , but there was no apparent dose-response relationship, providing a weak support for an association between PAH-DNA adducts and breast cancer. No association with breast cancer was found in a case-control study where DNA adducts in white blood cells (WBC) were measured by 32 P-post-labelling method (18) . So far only one prospective study has analyzed the risk of breast cancer in relation with pre-diagnostic bulky adducts in DNA from WBC, detected by the 32 P-post-labelling, using a nested casecontrol design (19) ; multivariate analyses failed to show any significant association. In the present study, we examine the potential association between aromatic DNA adducts measured in WBC by 32 P-post-labelling method and the risk of breast cancer in Spanish women using a prospective case-cohort design.
Materials and methods

Study design: setting, participants and data collection
The study subjects were participants from the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC), following a case-cohort design. The EPIC-Spain cohort includes 41 438 subjects (25806 women) with age 29-69 years recruited between 1992 and 1996 in five Spanish provinces (Asturias, Gipuzkoa, Navarra, Murcia and Granada). Further details about the EPIC cohort can be found elsewhere (20) .
The population for this study was selected according to a case-cohort design within the EPIC-Spain cohort (21) . The subcohort consisted of 300 subjects (60 from each centre) randomly selected according the age-sex structure of Spanish population. Biological material was not available for four participants leaving 296 individuals (147 men and 149 women) valid for DNA analysis. Case ascertainment was based on record linkage of the whole EPIC-Spain cohort with population cancer registries of the five regions where the cohort was recruited; moreover dates and causes of death were obtained by crossing data with the National Institute of Statistics. Cases were defined as first occurrence of a primary malignant tumor of the breast (C50 of the ICD-10). A total of 311 women were newly diagnosed of breast cancer during the 7-year follow-up; due to lack of biological material for six participants the analysis was carried out with 305 cases, one of which belonging to the subcohort. Information on the hormone receptor status was available for 127 (42%) of cases.
At recruitment information on diet and lifestyle factors, anthropometrical measurements, and 30 ml blood samples were collected. Usual diet throughout the year, accounting for seasonal variation, was estimated through a personal interview with a validated dietary history questionnaire (22, 23) . The dietary history included intake of alcoholic beverages, and therefore provided information of alcohol consumption at recruitment. The lifestyle questionnaire included questions on education, lifetime history of tobacco smoking, physical activity and reproductive history. Physical activity was assessed using a validated questionnaire focused on usual activity in occupational, household and recreational (including sport activities) domains (24) . Questions about reproductive history and related issues included menopausal status, lactation, ages at menarche, first full-term pregnancy (FFTP) and menopause, as well as use of oral contraceptives and hormonal replacement therapy. Anthropometric measurements, including height, weight and waist circumference, were taken by trained individuals; height and weight were then used to compute the body mass index (BMI) as kg/m 2 .
DNA adducts determination
DNA from WBC was analyzed using 0.5 ml aliquots of buffy coats stored in liquid nitrogen at −196°C. DNA purification was done using digestion with ribonuclease A, ribonuclease T1 and proteinase K, followed by phenol-chloroform extraction; coded DNA was stored at −80°C until laboratory analysis (25) . Aromatic DNA adducts were analyzed blindly using the nuclease P1 modification of the 32 P-DNA-post-labelling technique; details of the method have been previously reported (26, 27) . Detection of bulky DNA adducts was carried out by polyethyleneimine cellulose thin layer chromatography plates. The levels of DNA adducts were expressed as relative adduct labeling screen response in adducted nucleotides as compared to total nucleotides, with a detection limit of 0.1 × 10 −9 nucleotides (28) . The values of DNA adducts were corrected across experiments based on the recovery of Benzo(a)pyrene (BaP) DNA adduct standard that was analyzed in parallel.
Statistical methods
DNA adduct levels were expressed as adducted nucleotides per 10 9 normal nucleotides. Samples below the detection limit were assigned a value of 0.05 × 10 −9 (half the threshold of detection limit of the technique). Given the right-skewed distribution, this variable was log 2 -transformed, after adding a constant of 1 to avoid the strong influence of negative values (in the log-scale) of subjects whose adduct levels were very close to zero. The median with corresponding 25th and 75th percentiles were used as indicators of the DNA adduct concentration. Comparison of adduct levels between cases and the subcohort was based upon a t-test using geometric means adjusted by age, center and season; age and center were used as stratification variables in the selection of subjects while season of blood collection was found to be associated with adduct levels in the subcohort in previous analyses (29) .
The association between DNA adducts and breast cancer was evaluated by the relative risk (RR) and 95% confidence intervals based on the hazard ratios from a proportional hazards model (Cox regression).
Abbreviations
BMI
body mass index ER estrogen receptor FFTP first full-term pregnancy PAH polycyclic aromatic hydrocarbons PR progesterone receptor A modified partial likelihood was used to take into account the casecohort design, applying the weighting method proposed by Prentice, as it provides the estimates that most resemble those of the full cohort (30) . Adduct levels were evaluated using both a categorical variable based on tertiles in the subcohort and the continuous variable. It must be taken into account that the adduct concentration has been log-transformed and therefore the relationship between exposure and risk is assumed to be log-linear. On the other hand, since the logarithm used was the log 2 , the estimated RR for this variable must be interpreted as the multiplicative factor of breast cancer risk associated with a doubling in the level of DNA adducts. Two models were built using Cox regression. The minimally adjusted model included age and center to take into account the stratified design of the subcohort, as well as season of blood extraction, found to be associated with adduct levels in the subcohort in previous analyses. The multivariate model was built upon the minimally adjusted model to account for the possible effect of confounders, with further inclusion of the following covariates: education, physical activity, BMI, waist circumference, height, age at menopause, age at menarche, age at FFTP, lactation, use of oral contraceptive, alcohol consumption, total fat intake and energy intake. To take into account the differential effect of BMI for pre-or post-menopausal women (31) , an interaction term between BMI and menopausal status was included. The analyses were applied to all breast cancer cases and by hormone receptor status of the tumor: estrogen receptor (ER) and progesterone receptor (PR).
Subgroup analysis was carried out for pre-and post-menopausal women; for the latter, the multivariate model included also use of hormonal replacement therapy. We also explored the potential effect modification of BMI, age at FFTP and tobacco smoking on the risk of breast cancer. Interaction between these variables and the adduct levels was assessed by comparing the likelihood of the model with the corresponding interaction terms and the model containing terms for the main effects only by means of the likelihood ratio test (32) .
Results
The baseline characteristics of women from the subcohort and breast cancer cases are shown in Table 1 . Cases were slightly older than women from the subcohort (mean age 48.8 and 47.8 years, respectively). Both groups were relatively similar regarding education, smoking status, alcohol consumption and level of physical activity. Cases tended to have greater BMI but no statistically significant differences were found for BMI or waist circumference. About half of women were post-menopausal both among cases and in the subcohort. Both groups showed similar patterns for most variables related with reproductive history, unless for age at FFTP, with a significantly higher proportion of cases (51%) with FFTP above 25 years as compared with 39% for women from the subcohort.
Aromatic adduct concentrations were higher in breast cancer cases than in the subcohort, with adjusted geometric means 7.7 and 5.9 adducts per 10 9 normal nucleotides respectively (P-value 0.0001) as shown in Table 2 . The adjusted arithmetic means were 9.4 × 10 −9 for cases and 8.4 × 10 −9 for women from the subcohort, while both series had similar medians. Regarding hormonal receptor status, only four cases were ER−/PR+; for the remaining combinations of ER and PR, as well as for those without ER/PR information, the level of DNA adducts were higher in the case series as compared with the subcohort, although the differences for the ER− and ER−/PR− did not reach statistical significance probably owing to small number of cases.
The distribution of the DNA-adduct concentration according to variables assumed to be relevant for breast cancer risk (menopausal status, BMI, age at FFTP and smoking) is shown in Figure 1 . There is large dispersion of values of adduct concentrations with a skewed trend toward higher values, confirming that logarithmic transformation was appropriate to deal with this variable. Overall there seems to be higher DNA-adduct levels among breast cancer cases than among women from the subcohort in most strata; significant differences when comparing means (log-transformed variable, adjusted for age, center and season) were observed among post-menopausal women, those with BMI <25 kg/m 2 , women whit FFTP at age 25 years or above and never smokers.
Breast cancer risk was found to be positively associated with concentrations of aromatic DNA adducts in WBC (Table 3) . After adjusting for relevant confounders, the risk of breast cancer increased significantly by 61% when doubling the concentration of DNA adducts, as indicated by the RR of 1.61 (95% confidence interval 1.29-2.01) for the adduct level in the log 2 scale. The effect seems to be higher among cases positive for estrogen receptors (RR = 1.79) than among ER− (RR = 1.36); the latter was not statistically significant but this comparison had small statistical power as it was based only upon 29 cases. In spite of the apparent trend in the categorical analysis, the RRs for the highest versus lowest tertiles of adduct levels did not reach statistical significance. Although most breast cancer risk factors were not significantly different in our cases and subcohort, as shown in Table 1 , overall they showed a relevant confounding effect when considered altogether. The minimally adjusted (age, centre, season) RR for the log 2 of DNA adduct level of 1.29 increased by 25% up to 1.61 when relevant confounders were accounted for in the multivariate model.
The positive association between breast cancer and DNA adducts was evident (and significant) both in pre-and postmenopausal breast cancer cases (Table 4 ). The effect seems to be higher in post-menopausal (RR = 2.04) than in pre-menopausal women (RR = 1.74) although the difference between these estimates was not statistically significant. Doubling the concentration of DNA adducts was significantly associated with a high risk of breast cancer (RR = 2.76) among women with normal weight (below 25 kg/m 2 ), whereas no significant association was seen for overweight or obese women, with a significant interaction. There is also a significant interaction between DNA adduct levels and smoking status in relation with the risk of breast cancer, with RR above two for former and current smokers and 1.34 for never smokers; however, even in the latter case the association was significant. Finally the association between breast cancer and DNA adduct concentration was significant only for women whose age at FFTP was 25 years or older, but there was no significant interaction between these variables.
Discussion
We observed that levels of bulky DNA adducts in WBC are associated with the risk of breast cancer: taking into account relevant confounders, our results indicate an increase in risk of breast cancer by 61% when doubling the concentration of DNA adducts. The increased risk was observed both for pre-and postmenopausal women, and seems to be higher among women bearing tumors with positive ER. Our data also suggest that the association is more marked for ever than for never smoker women, and seems to be confined to those with normal weight.
Overall our results tend to agree with previous studies based upon DNA adducts measured in breast tissue (12, 13, 15) , but are in disagreement with those reported in large case-control studies (8, 17) or prospective studies (19) that detected adducts in peripheral blood. In the population-based case-control study among women on Long Island (8), a modest elevation in the risk of breast cancer was noted in relation to the highest quintile of PAH-DNA adduct levels but no dose-response effect was observed. These results, coupled with the observed 50% increase in risk among women with detectable adducts, suggests that there may be a threshold effect, while we observed an increasing risk of breast cancer with increasing levels of DNA adducts. The immunoassay method used in the Long Island study (8) is known to be less sensitive than the 32 P-post-labelling method used in our study, but it is selective for PAH, while the latter is unable to specify the exact composition of the detected adducts. In fact, the 32 P-postlabelling technique is known to be sensitive for the detection of a wide range of bulky and hydrophobic adducts in addition to those induced by PAH, such as nitro-aromatic compounds and heterocyclic amines (25, 26) . Another difference between these two studies is related to the different time frame for exposure due to the source of DNA. The Long Island study (8) used peripheral mononuclear cells, with a cell life-span as long as 3 years, while we used a mixture of WBC, including different subpopulations with life-span varying from a few days to several years, and therefore the actual time frame of exposure is uncertain (33) .
The most important difference between ours and the abovementioned studies (8,12,13,15,17) concerns the study design. All of them are case-control studies; owing to their retrospective nature they have a limited ability to establish causality as the biomarker may reflect the disease rather than the exposure. However, we also found discrepancies with the results of the nested case-control study within the EPIC-Italy, reporting no association between DNA adducts and breast cancer risk (19) . Both studies have similar features: they used a prospective design with blood samples collected well before cancer diagnosis, ruling out the possibility that adduct levels were related to the presence of disease; moreover both studies used DNA from WBC and measured adducts using exactly the same method. The background level of adducts was slightly higher in the Italian study (19) : the average DNA-adducts concentration in the control group was 11 × 10 −9 nucleotides, whereas it was 8.4 × 10 −9
in our subcohort. There were also some minor differences in the baseline characteristics of the population: controls from the Italian study (19) included 52% post-menopausal women, 49% with overweight or obesity, and 54% never smokers; the corresponding values from our subcohort were 43, 66 and 76%, respectively (Table 1) . DNA adduct levels have been shown to be subjected to seasonal variations; this has been accounted for in our study, as well as in the population-based case-control study in Long Island (8, 17) , but not in the Italian study (19) . However the seasonal variations has little influence in our effect estimates: the RR 1.61 (1.29-2.01) of the adduct concentration (in the log 2 scale) of the multivariate model (Table 3) reduced only to 1.57 (1.26-1.95) when season was eliminated from the model. Our analysis included a few more confounders but it is unlikely that this accounts for the different results as we found a significant association even in the minimally adjusted estimate (Table 3) . It must be noted that both prospective studies, as well as the Long Island study (8, 17) , measured DNA in peripheral blood, under the assumption that they are a surrogate for those at the target tissue. Some studies that assessed adduct levels in a variety of target and surrogate tissues from the same individuals found strong correlations, whereas others have not (34, 35) . However, specific data about the correlation between DNA adducts detected in blood and breast tissue are not available. Stratified analysis by menopausal status, body mass index, first full-term pregnancy and tobacco smoking. a Adjusted for age, centre, season of blood extraction, education, physical activity, BMI (interaction with menopausal status), waist circumference, height, age at menopause, age at menarche, age at FFTP, lactation, use of OC, alcohol consumption, total fat intake and energy intake; the model for post-menopausal women included also ever use of HRT. Menopause, BMI and age at FFTP were excluded when used as variables of stratification. We observed that the concentration of DNA-adducts was higher in women with ER+ than in ER− tumors. Moreover, the association with breast cancer risk was also higher for ER+ than for ER−, although our study had limited statistical power for this subgroup analysis. Our results are in agreement with an ecological study looking at the relationship between incidence rates of breast cancer and environmental factors (4) . Only ER+ breast cancers were positively associated with an index of estimated risk of cancer based on toxic air emissions including several chemicals known to be endocrine disruptors, including some xenoestrogens. Molecular studies have also shown that BaP exhibits estrogenic activity in the ER-CALUX assays, most likely due to induction of cytochrome P450 enzymes and by aryl hydrocarbon receptor activation (36) , and that increased formation of BaP-DNA adducts may be mediated through ERα expression by estradiol (37) . On the contrary, in some studies PAH have exhibited either weakly estrogenic or antiestrogenic responses (38) , and PAH detected in environmental samples induced antiestrogenic responses in metabolically intact human breast cancer cells (39) .
The higher risk of breast cancer associated with increasing levels of aromatic DNA adduct seems to be modified by tobacco smoking and BMI. In contrast with previous studies (8,19) we did not adjust by smoking history. Even though several epidemiological studies including large cohort studies (40, 41) consistently showed a small positive association, the evidence that tobacco smoking causes breast cancer in humans is still considered as limited (42) . On the other hand, interpreting the effect of adducts after adjusting for smoking would be problematic, since tobacco smoke is a source of PAH exposure and therefore adduct levels could be an intermediate variable between smoking and breast cancer (43) . Instead, we explored the potential role of smoking as effect modifier; we observed a higher effect of adducts on breast cancer risk among smokers (either former or current smokers), though a smaller but significant effect remained among never smoker women. An association between DNA adducts and cancer predominantly in current smokers has been often reported for smoking related cancers (34) , but it has not been observed for breast cancer (8, 17, 19) . One plausible explanation for this effect modification by smoking could result from the tumor promoting effects of cigarette smoke. Owing to its content of PAH and other carcinogens, smoking would first play a role as contributor to adduct formation, and then strengthen the risk associated with these adducts.
We also found that the effect of aromatic DNA adducts on breast cancer risk was confined to women with normal weight (BMI below 25 kg/m 2 ). To our knowledge, this is a new finding, although an analog result had been reported in the Women's Health Initiative study for cigarette smoking (44) . In this cohort study a significant association between smoking and breast cancer risk was noted in non-obese but not in obese post-menopausal women. One of the possible explanations for this may be that smoking has been reported to lower the level of estrogen (45), a primary mediator of the mechanism by which obesity could promote the risk of breast cancer in post-menopausal women. This rationale, however, applies to tobacco smoke, not to the specific compounds involved in aromatic adducts formation.
Among the limitations of our study are the sample size, the relatively high proportion of cases without information on hormone receptors, and the lack of information about HER2 status. The latter precluded us to extend our analysis to the triple-negative breast tumors, a subgroup of particular interest concerning to the prognosis. Regarding sample size, it is relatively small, mainly for the subgroup analyses. The statistical power is also affected by the small number of controls. We have an unbalanced number of cases and controls owing to the case-cohort design of our study, aimed to analyze the potential association of aromatic adducts with several tumors, including cancers of the lung, stomach, colon and rectum. While the sex distribution was well suited to assess the association with the above-mentioned tumors, we ended up an inefficient sample size for the analysis of breast cancer.
To conclude, the results from our study support the hypothesis that factors involved in the formation of aromatic DNA adducts may be involved in the development of breast cancer. The association between increasing levels of bulky adducts in WBC and breast cancer risk seems to be independent of menopausal status, and is higher among women with ER+ tumors, although the association among women with ER− cannot be ruled out. The effect of DNA adducts on breast cancer risk is higher among smokers, and seems to be restricted to women with normal weight, but specific mechanisms underlying such interactions remain unclear. 
